S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
Log in

NASDAQ:WVE - Wave Life Sciences Stock Price, Forecast & News

$7.85
-0.62 (-7.32 %)
(As of 02/27/2020 04:00 PM ET)
Today's Range
$7.75
Now: $7.85
$8.29
50-Day Range
$6.94
MA: $7.93
$9.72
52-Week Range
$6.89
Now: $7.85
$48.64
Volume557,253 shs
Average Volume763,836 shs
Market Capitalization$269.18 million
P/E RatioN/A
Dividend YieldN/A
Beta0.67
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:WVE
CUSIPN/A
Phone65-6236-3388

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.41 million
Book Value$2.49 per share

Profitability

Net Income$-146,650,000.00
Net Margins-1,015.84%

Miscellaneous

Employees250
Market Cap$269.18 million
Next Earnings Date3/2/2020 (Confirmed)
OptionableOptionable

Receive WVE News and Ratings via Email

Sign-up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.


Wave Life Sciences (NASDAQ:WVE) Frequently Asked Questions

What is Wave Life Sciences' stock symbol?

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd (NASDAQ:WVE) posted its quarterly earnings data on Tuesday, November, 5th. The company reported ($1.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.34) by $0.14. The firm earned $2.93 million during the quarter, compared to analyst estimates of $6.30 million. Wave Life Sciences had a negative return on equity of 128.21% and a negative net margin of 1,015.84%. View Wave Life Sciences' Earnings History.

When is Wave Life Sciences' next earnings date?

Wave Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Wave Life Sciences.

How can I listen to Wave Life Sciences' earnings call?

Wave Life Sciences will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for WVE?

8 brokerages have issued 1 year price objectives for Wave Life Sciences' stock. Their forecasts range from $10.00 to $65.00. On average, they expect Wave Life Sciences' share price to reach $25.00 in the next year. This suggests a possible upside of 218.5% from the stock's current price. View Analyst Price Targets for Wave Life Sciences.

What is the consensus analysts' recommendation for Wave Life Sciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Wave Life Sciences.

What are Wall Street analysts saying about Wave Life Sciences stock?

Here are some recent quotes from research analysts about Wave Life Sciences stock:
  • 1. According to Zacks Investment Research, "WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore. " (2/18/2020)
  • 2. HC Wainwright analysts commented, "Our $33 target is based on a risk-adjusted, sum-of-the-parts DCF analysis: beta of 1.16, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.0%, and tax rate of 15% beginning in FY 2030, and is now 100% leveraged to the company’s CNS portfolio. Risks to our target include: commercial, reimbursement, regulatory, along with clinical and manufacturing. WAVE Life Sciences Ltd." (7/31/2019)

Has Wave Life Sciences been receiving favorable news coverage?

News articles about WVE stock have been trending extremely negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Wave Life Sciences earned a media sentiment score of -4.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Wave Life Sciences.

Are investors shorting Wave Life Sciences?

Wave Life Sciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 6,440,000 shares, an increase of 46.4% from the January 15th total of 4,400,000 shares. Based on an average daily volume of 882,200 shares, the short-interest ratio is currently 7.3 days. Approximately 24.8% of the shares of the company are short sold. View Wave Life Sciences' Current Options Chain.

Who are some of Wave Life Sciences' key competitors?

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Novavax (NVAX), TherapeuticsMD (TXMD), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Agile Therapeutics (AGRX), Cidara Therapeutics (CDTX) and Eyepoint Pharmaceuticals (EYPT).

Who are Wave Life Sciences' key executives?

Wave Life Sciences' management team includes the folowing people:
  • Dr. Paul B. Bolno, Pres, CEO & Director (Age 45)
  • Dr. Christopher Francis Ph.D., Sr. VP of Corp. Devel. & Head of Emerging Areas (Age 41)
  • Dr. Chandra Vargeese, Sr. VP of Drug Discovery (Age 58)
  • Dr. Takeshi Wada, Scientific Advisor (Age 57)
  • Mr. Keith C. Regnante, Chief Financial Officer (Age 49)

Who are Wave Life Sciences' major shareholders?

Wave Life Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (2.89%), Janus Henderson Group PLC (2.34%), State Street Corp (1.40%), FMR LLC (0.61%), Point72 Asset Management L.P. (0.46%) and Spark Investment Management LLC (0.38%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View Institutional Ownership Trends for Wave Life Sciences.

Which major investors are selling Wave Life Sciences stock?

WVE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Spark Investment Management LLC, State Street Corp, New York State Common Retirement Fund, Bank of America Corp DE, Platinum Investment Management Ltd. and ProShare Advisors LLC. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Gregory L Verdine, Michael A Panzara and Paul Bolno. View Insider Buying and Selling for Wave Life Sciences.

Which major investors are buying Wave Life Sciences stock?

WVE stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Assenagon Asset Management S.A., Pictet Asset Management Ltd., Citigroup Inc., California Public Employees Retirement System, Amia Capital LLP, NJ State Employees Deferred Compensation Plan and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Wave Life Sciences.

How do I buy shares of Wave Life Sciences?

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Wave Life Sciences' stock price today?

One share of WVE stock can currently be purchased for approximately $7.85.

How big of a company is Wave Life Sciences?

Wave Life Sciences has a market capitalization of $269.18 million and generates $14.41 million in revenue each year. The company earns $-146,650,000.00 in net income (profit) each year or ($5.06) on an earnings per share basis. Wave Life Sciences employs 250 workers across the globe.View Additional Information About Wave Life Sciences.

What is Wave Life Sciences' official website?

The official website for Wave Life Sciences is http://www.wavelifesciences.com/.

How can I contact Wave Life Sciences?

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]


MarketBeat Community Rating for Wave Life Sciences (NASDAQ WVE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  307 (Vote Outperform)
Underperform Votes:  270 (Vote Underperform)
Total Votes:  577
MarketBeat's community ratings are surveys of what our community members think about Wave Life Sciences and other stocks. Vote "Outperform" if you believe WVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel